

In the Claims:

Please amend the Claims as follows (the changes in these Claims are shown with ~~strikethrough~~ for deleted matter and underlines for added matter). A complete listing of the claims with proper claim identifiers is set forth below.

Claims 1 – 57 (cancelled).

Claim 58 (currently amended). A compound or pharmaceutically acceptable salt, hydrate, or solvate thereof selected from:

t-Butyl 1-[9-[1-(~~tert~~-butoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate,
Diethyl 10-oxo-2,2,18,18-tetramethyl-nonadecanedioate,

11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid ;

1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;

~~11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid ;~~

~~1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;~~

11-(1-Carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid,

1-[9-(1-Carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid,

1-[9-(1-Carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid,

13-(1-Carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid,

1-[11-(1-Carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropane carboxylic acid,

1-[11-(1-Carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentane carboxylic acid,

10-Oxo-2,2,18,18-tetramethyl-nonadecanedioic acid.

Claim 59 (previously presented). A compound of claim 58 wherein said compound is *t*-Butyl 1-[9-

[1-(~~tert~~-butoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 60 (previously presented). A compound of claim 58 wherein said compound is Diethyl 10-oxo-2,2,18,18-tetramethyl-nonadecanedioate, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 61 (currently amended). A compound of claim 58 wherein said compound is 44-(~~1-Carboxycyclopropyl~~)-2,2-dimethyl-7-oxoundecanoic acid, 11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 62 (previously presented). A compound of claim 58 wherein said compound is 1-[9-(1-Carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 63 (previously presented). A compound of claim 58 wherein said compound is 11-(1-Carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 64 (previously presented). A compound of claim 58 wherein said compound is 1-[9-(1-Carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 65 (previously presented). A compound of claim 58 wherein said compound is 1-(9-(1-

Carboxycyclopentyl]-5-oxononyl]-1-cyclopentylcarboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 66 (previously presented). A compound of claim 58 wherein said compound is 13-(1-

Carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 67 (previously presented). A compound of claim 58 wherein said compound is 1-[11-(1-

Carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropane carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 68 (previously presented). A compound of claim 58 wherein said compound is 1-[11-(1-

Carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentane carboxylic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 69 (previously presented). A compound of claim 58 wherein said compound is 10-Oxo-

2,2,18,18-tetramethyl-nonadecanedioic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 70 (new). A pharmaceutical composition comprising a compound of claim 58 or a pharmaceutically acceptable salt, hydrate, or solvate thereof and a pharmaceutically acceptable carrier.

Claim 71 (new). A method of increasing HDL levels, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound pharmaceutically acceptable salt, hydrate, or solvate thereof selected from:

t-Butyl 1-[9-[1-(tert-butoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate,
Diethyl 10-oxo-2,2,18,18-tetramethyl-nonadecanedioate,

11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid ;

1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;

11-(1-Carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid,

1-[9-(1-Carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid,

1-[9-(1-Carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid,

13-(1-Carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid,

1-[11-(1-Carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropane carboxylic acid,

1-[11-(1-Carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentane carboxylic acid,

10-Oxo-2,2,18,18-tetramethyl-nonadecanedioic acid.

Claim 72 (new). A method according to claim 71 wherein the compound is 11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 73 (new). A method according to claim 71 wherein the compound is 1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 74 (new). A method according to claim 71 wherein the compound is 11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 75 (new). A method according to claim 71 wherein the compound is 1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 76 (new). A method of decreasing LDL levels, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound pharmaceutically acceptable salt, hydrate, or solvate thereof selected from:

t-Butyl 1-[9-[1-(tert-butoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate,
Diethyl 10-oxo-2,2,18,18-tetramethyl-nonadecanedioate,
11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid ;
1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;
11-(1-Carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid,
1-[9-(1-Carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid,
1-[9-(1-Carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid,
13-(1-Carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid,
1-[11-(1-Carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropane carboxylic acid,
1-[11-(1-Carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentane carboxylic acid,
10-Oxo-2,2,18,18-tetramethyl-nonadecanedioic acid.

Claim 77 (new). A method according to claim 76 wherein the compound is 11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 78 (new). A method according to claim 76 wherein the compound is 1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 79 (new). A method according to claim 76 wherein the compound is 11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 80 (new). A method according to claim 76 wherein the compound is 1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid or a pharmaceutically acceptable salt, hydrate, or solvate thereof.